Integrated Diagnostics Holdings PLC (IDHC) - Total Liabilities
Based on the latest financial reports, Integrated Diagnostics Holdings PLC (IDHC) has total liabilities worth $3.67 Billion USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore IDHC net asset momentum to track the company's year-over-year net asset growth rate.
Integrated Diagnostics Holdings PLC - Total Liabilities Trend (2012–2024)
This chart illustrates how Integrated Diagnostics Holdings PLC's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Integrated Diagnostics Holdings PLC to measure how efficiently the company converts operating cash flow to free cash.
Integrated Diagnostics Holdings PLC Competitors by Total Liabilities
The table below lists competitors of Integrated Diagnostics Holdings PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Cynda Chemcial Co Ltd
SHG:603086
|
China | CN¥2.08 Billion |
|
Hyliion Holdings Corp.
NYSE MKT:HYLN
|
USA | $12.38 Million |
|
Qumei Furniture Group Co Ltd
SHG:603818
|
China | CN¥3.88 Billion |
|
Hibiscus Petroleum BHD
KLSE:5199
|
Malaysia | RM4.73 Billion |
|
Xiamen R&T Plumbing Technology Co Ltd
SHE:002790
|
China | CN¥451.31 Million |
|
Incar Financial Service Co. Ltd.
KQ:211050
|
Korea | ₩696.18 Billion |
|
Jiangsu Tianmu Lake Tourism Co Ltd
SHG:603136
|
China | CN¥176.11 Million |
|
Acco Brands Corporation
NYSE:ACCO
|
USA | $1.60 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Integrated Diagnostics Holdings PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Integrated Diagnostics Holdings PLC (IDHC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integrated Diagnostics Holdings PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integrated Diagnostics Holdings PLC (2012–2024)
The table below shows the annual total liabilities of Integrated Diagnostics Holdings PLC from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.63 Billion | +35.97% |
| 2023-12-31 | $2.67 Billion | -6.31% |
| 2022-12-31 | $2.85 Billion | -17.22% |
| 2021-12-31 | $3.44 Billion | +96.55% |
| 2020-12-31 | $1.75 Billion | +25.51% |
| 2019-12-31 | $1.40 Billion | +35.04% |
| 2018-12-31 | $1.03 Billion | +29.51% |
| 2017-12-31 | $797.72 Million | +6.90% |
| 2016-12-31 | $746.22 Million | +37.98% |
| 2015-12-31 | $540.83 Million | +42.48% |
| 2014-12-31 | $379.58 Million | +12.34% |
| 2013-12-31 | $337.90 Million | -9.60% |
| 2012-12-31 | $373.76 Million | -- |
About Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more